Open AccessPersistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
Author(s) -
Bazinet Michel,
Pântea Victor,
Cebotarescu Valentin,
Cojuhari Lilia,
Jimbei Pavlina,
Anderson Mark,
Gersch Jeff,
Holzmayer Vera,
Elsner Carina,
Krawczyk Adalbert,
Kuhns Mary C.,
Cloherty Gavin,
Dittmer Ulf,
Vaillant Andrew
Publication year - 2021
Publication title -
hepatology communications
Language(s) - English
Resource type - Journals
ISSN - 2471-254X
DOI - 10.1002/hep4.1633
Subject(s) - hbsag , virology , medicine , coinfection , hepatitis b virus , seroconversion , hepatitis d virus , entecavir , pegylated interferon , tolerability , hepatitis b , hepatitis d , virus , immunology , hepatitis c virus , lamivudine , ribavirin , adverse effect
Finite therapy of HBV/HDV co‐infection with REP 2139‐Ca and pegIFN has good long term safety and is accompanied by high rates of functional cure of HDV, normalization of liver function and additional functional cure of HBV. HBV functional cure is accompanied inactivation / clearance of cccDNA and clearance of integrated HBV DNA.